MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Psoriasis: Treatment and Pathogenesis
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,393 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,393 works in the cohort · of 4,299,418page 26 of 48

Labels cover 8 of 2,393 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,393 of 2,393 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
OP0230 EFFICACY AND SAFETY OF TILDRAKIZUMAB, A HIGH-AFFINITY ANTI–INTERLEUKIN-23P19 MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS IN A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE, PHASE 2B STUDY
Philip J. Mease, Saima Chohan, Ferran José García Fructuoso, Alice B. Gottlieb, Michael E. Luggen, Proton Rahman +5 more
2020· article· en· Annals of the Rheumatic Diseases· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
5
citations
affunlabeled
Psoriasis patients’ preference for an aerosol foam topical formulation
Ronald Vender, Melinda Gooderham, Lyn Guenther, Dimitrios Kyritsis, Jaggi Rao, Agnieszka Kowalczyk +1 more
2018· letter· en· Journal of the European Academy of Dermatology and Venereology· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
5
citations
affunlabeled
POS1072 Icotrokinra, a Targeted Oral Peptide That Selectively Blocks the Interleukin-23-Receptor, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3, Randomized, Double-Blind, Placebo-Controlled ICONIC-LEAD Trial
Robert Bissonnette, Jennifer Soung, Adelaide A. Hebert, Andrew Pink, Andreas Pinter, Yi Shi +6 more
2025· article· en· Annals of the Rheumatic Diseases· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
5
citations
affno abstractunlabeled
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial
Vipul Jairath, Silvio Danese, Geert D’Haens, Brian G. Feagan, Laurent Peyrin-Biroulet, Bruce E. Sands +8 more
2025· article· en· ˜The œLancet. Gastroenterology & hepatology· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
5
citations

How this was built: Screen · Findings · About